Clinical Trial Update: EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating pharmacogenetic-guided dosing of acenocoumarol for venous thromboembolism and atrial fibrillation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Venous Thromboembolism

Drugs mentioned

• Acenocoumarol (Acenocoumarol)

Snippet

Sponsor: Utrecht Institute for Pharmaceutical Sciences | Conditions: Venous Thromboembolism, Atrial Fibrillation | Phase 4 | Status: COMPLETED